Clinical Trial Search

Primary: Migraine Frequency at 12 Weeks — -5.5; -3.9 days

Primary: Total Number of Responders — 17 Participants

Primary: Change in Migraine Characteristics — 43; 2; 17 Participants

Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale

Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants

Primary: Percent Change of Headache Days Compared to Baseline — -13.50; -36.50 percent change of headache days

Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month

Primary: Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline — 4.4; 4.7 Moderate to severe headache days…

Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days

Primary: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3 — -23.38; -31.33 hours/month — p=< 0.001

Primary: Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE) — 41; 151 Participants — p=<.001

Primary: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) — 91 Participants

Primary: Number of Participants Who Completed Initially Assigned Treatment and Achieved at Least a 50% Reduction From Baseline in Monthly Migraine Days at Month 12 — 232; 35…

Primary: Percentage of Participants Experiencing no Pain at Two Hours Post-treatment — 39; 22 percentage of participants

Primary: Assessment of Recruitment Rate — 1.1; 0.6 participants per month

Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03

Primary: Primary Efficacy Endpoint - Percentage of Subjects With a 50% Reduction From Baseline in the Monthly Number of Migraine Attacks at 12 Months. — 32; 38 percentage of…

Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants

Primary: Pain Relief at 2 Hours After the Initial Dose of Test Drug — 285; 322; 106; 172 Participants

Primary: DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab — -0.6; -3.7; -4.1 days/month…

Primary: Number of Subjects With Pain Relief at 2 Hours From Time of First Dose — 136; 231 participants

Primary: Headache Pain Relief at 2 hr Post-dose by 2-point Definition — 6; 11; 13 Participants

Primary: Number of Participants With Adverse Events — 110; 85; 79 Participants

Primary: Change From Baseline in Monthly Migraine Days (Weeks 1-12) — -4.3; -3.9; -4.1; -3.1 Migraine Days — p=0.0001

Primary: Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate — 1.35; 2.12 Migraine attacks

Primary: Headache Days — 23.64; 24.33 Days — p=0.83

Primary: Percentage of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment — 66; 40 Participants

Primary: Change in Number of Migraine Episodes Per 30 Days at Month 10. — -2.1; -2.1; -2.2; -3.3 Number of Migraine episodes — p=< .01

Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days

Primary: Migraine Headache Days — 7.12; 6.92; 5.53; 4.79 Days